seratrodast has been researched along with Epilepsy in 1 studies
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, Y | 1 |
| Ou, Y | 1 |
| Zhang, C | 1 |
| Chen, H | 1 |
| Yue, H | 1 |
| Yang, Z | 1 |
| Zhong, X | 1 |
| Hu, W | 1 |
| Sun, P | 1 |
1 other study available for seratrodast and Epilepsy
| Article | Year |
|---|---|
Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation.
Topics: Animals; Benzoquinones; Epilepsy; Ferroptosis; Glutathione; Heptanoic Acids; Mice; Pentylenetetrazol | 2022 |